In case you missed our email last week, we shared 8 fantastic immunotherapy experts confirmed to speak at Phar-East 2018, Singapore, taking place 28th February to 2nd March. Speaking on their latest work, these distinguished speakers from Asia pharma industry will share their experience, lessons learnt and future plans.
First of all, we have Frank Jiang, CEO and founder of CStone. Recently successfully securing funding of a rather impressive 150 million dollars, CStone has an exciting plan for cancer immunotherapy. Frank will join us to share with us his knowledge of “Cancer precision medicine: From screening to drug selection and development” with some case study from his own company to answer the big question on making highly personalised medicine to patients in need.
Next, we have Han Chong Toh, Chief Medical Officer of Tessa Therapeutics, a Singapore based biotech company working on a promising pipeline to treat solid tumors using immunotherapy. Han Chong is a renowned specialist in the National Cancer Center Singapore, conducted the first cancer vaccine and T cell vaccines in Singapore, and published over 93 review paper throughout his career. He will be speaking on “Awakening the immune system against cancer- moving into the clinic” on 1st March 2017 along with his colleague, John Connolly, Chief Scientific Officer.
Cristina Chang, VP clinical Development, Operations and Medical Affairs at OBI Pharma, a 15 year publicly listed biopharma company in Taiwan, will also be joining us. While Cristina and her team is working hard to complete the phase 2/3 study of this breast cancer vaccine pipeline, she has kindly spared some time to join us in Singapore next March to share about breast cancer vaccines and her lessons learnt so far, drawn from her hands-on experience working on the Adagloxad Simolenin (formerly OBI-822) pipeline.
Beside solid tumor immunotherapy and cancer vaccines, we bring you a case study on anti-viral immunotherapy from Singapore LionTCR led by Victor Li and Antonio Bertoletti. As you may know, LionTCR is a clinical stage biotech company that recently received FDA approval for orphan drug designation on HBV specific TCR redirected T cell therapies against HCC with transient mRNA and a longer lasting DNA transduction technologies. There is much excitement and innovation going on within TCR which we will leave the details to be explained by Victor and Antonio at Phar East next March.
Moving on from innovation in north east and south-east Asia, the next highlight is APAC Biotech , a clinical stage biotech company in India which recently secured CDSCO (Indian FDA) approval for the first dendritic cancer vaccine in the country. APAC Biotech was granted with a commercial license to market product, APCEDEN®, a Dendritic cell-based autologous Immuno-oncology product for four cancer indication namely Prostate, Ovarian, Colo-rectal and Non-Small Cell Lung carcinoma. Find out more from Bandana Sharan, Director of R&D from her session next March.
Combination therapy is another popular method in current immunotherapy studies, says Junjian Liu, VP of BIologics Discovery of Innovent, China. Innovent has traditionally been in the field of biosimilars and antibodies, like most of its peers recently shifting its focus to explore the power of the immune system in drug development. Junjian will be speaking on the building of a framework of combination Immuno-oncology from his recent experience setting up the studies for I-O in China. He will also be sharing on the latest progress, lessons learnt and the future prospect of combination I-O at Phar-East.
Further to the topic of combination immunotherapy, we also invited Skye Hung-Chun Cheng, Chief Scientist of Amwise Diagnostic which has offices in Singapore and Taiwan. Amwise Diagnostic specialises in genetic diagnostic tool and advanced precision medicine in oncology. He will be sharing on using molecular analytics to create effective combination, as well as tapping on to big data and analytics for disease modeling and prediction.
Last but not least, Jin-San Yoo, CEO of PharmAbcine from South Korea will speak on another discussion on combination of Tanibirumab + anti-PD1 antibody for refractory cancer patients. PharmAbcine is a regular supporter for Biopharma Asia conference which now rebranded into Phar-East 2018. In this presentation, JinSan will be sharing insights learnt from Tanibirumab recurrent GBM phase IIa open labelled three arms multi centre trial in Australia. He will also be speaking on the expansions of trails and combination of Tanibirumab + anti-PD1 antibody for refractory tumours at the conference.
Phar-East 2018’s full program will bring you over 120 speakers – these are just 8 of them! Find out more from our website: www.terrapinn.com/phar-east/
About Phar-East 2018
From humble beginnings as BioMedical Asia in 2008, BioPharma Asia has attracted close to 20,000 attendees over the last 10 years. Established as a true one-stop shop for all things biopharma, our 2018 program is rebranded into Phar East 2018 to explore innovation in clinical trials, manufacturing, supply chain, market access, partnering, pricing, and more without restricting itself on the type and nature of therapeutic products. Visit our website for more information: www.terrapinn.com/phar-east/